Fresenius Kabi Oncology Ltd - Stock Valuation and Financial Performance

BSE: 532545 | NSE: FKONCO | Pharmaceuticals & Drugs | Small Cap

BSE Share Price
Not Listed

DeciZen - make an informed investing decision on Fresenius Kabi Oncol

M-Cap below 100cr DeciZen not available

Fresenius Kabi Oncology stock performance -

mw4me loader
P/E Ratio (SA):
0.00
Market Cap:
2,254.9 Cr.
52-wk low:
132
52-wk high:
132.6

Is an attractive stock to invest in?

1. Is a good quality company?

Data is not available for this company.

2. Is undervalued or overvalued?

No data found

3. Is a good buy now?

No data found

10 Year X-Ray of Fresenius Kabi Oncol:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Value Creation

Value Creation Index Colour Code Guide

Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19TTM
ROCE % 13.3%7.4%4%10.8%-11%-16.2%-4.2%3.1%8.7%4.3%-
Value Creation
Index
-0.1-0.5-0.7-0.2-1.8-2.2-1.3-0.8-0.4-0.7-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 411413527596408464542624703660660
Sales YoY Gr.-0.4%27.6%13.2%-31.6%13.7%16.7%15.2%12.7%-6.2%-
Adj EPS 5.131.35.4-6.4-9.3-3.40.22.90.8-3.2
YoY Gr.--40.8%-57.8%324.4%-219.1%NANANA1731.3%-73.7%-
BVPS (₹) 31.134.237.542.635.530.725.925.826.923.934.3
Adj Net
Profit
80.447.620.185.4-102-159-572.849.813.1-54
Cash Flow from Ops. 55.850174127-52.7-1217.9-39.111298.4-
Debt/CF from Ops. 4.86.70.91.1-5.9-2.953.1-13.34.34.7-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 5.4%10.1%6.8%-6.2%
Adj EPS -18.9%NANA-73.7%
BVPS-2.9%-7.6%-2.6%-11.2%
Share Price - - - -

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19TTM
Return on
Equity %
17.89.23.513.5-16.5-29.3-11.90.611.13-10.9
Op. Profit
Mgn %
24.817.912.624-18.2-20.61.113.919.113.8-16.5
Net Profit
Mgn %
19.511.53.814.3-24.9-34.2-10.50.47.12-8.2
Debt to
Equity
0.60.60.30.20.60.711.211.1-
Working Cap
Days
402452374353575523438409427473305
Cash Conv.
Cycle
173222186170267214198185176168156

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to %

Sales growth has been subdued in last 3 years %

Net Profit has been subdued in last 3 years %

Sales growth is not so good in last 4 quarters at %

Latest Financials - Fresenius Kabi Oncology Ltd.

Standalone Consolidated
TTM EPS (₹) -3.2 0.9
TTM Sales (₹ Cr.) 660 516
BVPS (₹.) 34.3 15.6
Reserves (₹ Cr.) 566 248
P/BV 3.87 8.50
PE 0.00 140.86
From the Market
52 Week Low / High (₹) 132.00 / 132.60
All Time Low / High (₹) 27.05 / 193.75
Market Cap (₹ Cr.) 2,255
Equity (₹ Cr.) 17
Face Value (₹) 1
Industry PE 48.2

Management X-Ray of Fresenius Kabi Oncol:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Fresenius Kabi Oncol

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19
Sales411.28412.77526.77596.30408.17464.14541.56624.01703.48659.57
Operating Expenses 309.61339.11460.83453.30484.04559.88553.36539.64572.43569.14
Manufacturing Costs91.6085.24126.15157.26177.91180.1886.5485.1875.9675.56
Material Costs103.40135.34214.93164.96156.77228.23241.68251.71273.60269.24
Employee Cost 45.9556.1158.5867.806978.16115.61124.43143.21143.47
Other Costs 68.6662.4261.1763.2880.3673.31109.5378.3279.6780.87
Operating Profit 101.6773.6665.94143-75.87-95.73-11.8084.38131.0590.43
Operating Profit Margin (%) 24.7%17.8%12.5%24.0%-18.6%-20.6%-2.2%13.5%18.6%13.7%
Other Income 16.3328.612.901.808.5552.5512.7711.6528.2041.88
Interest 19.4018.0317.66-2.6012.5924.5629.2136.6345.8636.80
Depreciation 12.5116.9223.9725.7930.8944.3152.1048.7154.8354.62
Exceptional Items 02.6844.48-6.81-12.44-42.20-18.62-8.54-40.13-102.23
Profit Before Tax 86.097071.70114.81-123.26-154.25-98.952.1518.42-61.33
Tax 5.8720.7620.7534.22-11.902.86-16.344.57-1.16-7.41
Profit After Tax 80.2349.2450.9580.59-111.35-157.12-82.62-2.4219.58-53.92
PAT Margin (%) 19.5%11.9%9.7%13.5%-27.3%-33.9%-15.3%-0.4%2.8%-8.2%
Adjusted EPS (₹)5.13.13.25.1-7.0-9.2-4.9-0.11.2-3.2
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19

Equity and Liabilities

Shareholders Fund 492.10541.34592.59673.18561.83522.20440.53438.35458.17406.84
Share Capital 15.8215.8215.8215.8215.8217.0217.0217.0217.0217.02
Reserves 476.28525.52576.77657.36546505.17423.51421.33441.15389.82
Minority Interest0000000000
Debt269.09332.95147.31140.16310.69349.48421.25520.80474.47462.87
Long Term Debt269.0995.2295.2295.22121.3998.67170.38308.46308.46308.46
Short Term Debt0237.7352.0944.94189.30250.82250.86212.34166.01154.41
Trade Payables71.9981.2693.5991.36186.60196.88197.60160.89163.96222.22
Others Liabilities 78.44103.67176.64249.95167.20175.97119.56227.40263.34262.38
Total Liabilities 911.621,059.231,010.141,154.661,226.321,244.541,178.941,347.431,359.941,354.31

Fixed Assets

Gross Block241.88321.01390.35460.52596.28662.53574.38594.83641.47686.62
Accumulated Depreciation46.7862.7185.43108.79133.60179.1552.03100.57172.75230.14
Net Fixed Assets195.10258.30304.92351.74462.68483.38522.35494.26468.72456.48
CWIP 57.7795.57140.37163.0778.9955.2030.3944.6437.5537.02
Investments 129.40126.280.030.030.030.030.030.030.030.03
Inventories190.20207.22186.56245.09324.55340.18384.41399.50382.23386.01
Trade Receivables150.48176.59201.72185.08111.43118.02133.33142.74162.16149.27
Cash Equivalents 34.9518.5013.120.491.760.852.348.261.641.97
Others Assets153.73176.76163.41209.16246.88246.88106.10257.99307.62323.54
Total Assets 911.621,059.231,010.141,154.661,226.321,244.541,178.941,347.431,359.941,354.31

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19
Cash Flow From Operating Activity 55.8050.04174.29127.41-52.73-121.487.93-39.12111.6398.41
PBT 83.937071.70114.81-123.26-154.25-98.952.1518.42-61.33
Adjustment 41.8828.4840.6222.8965.8322.9388.3969.59119.3196.51
Changes in Working Capital -38.56-32.9774.8117.4816.410.0918.69-110.48-19.8266.68
Tax Paid -12.06-15.46-12.84-27.77-11.70-0.24-0.20-0.37-6.28-3.46
Cash Flow From Investing Activity -62.59-115.7316.82-120.42-85.58-44.06-39.16-32.69-28.03-52.21
Capex -62.58-121.21-110.66-120.82-77.54-36.90-36.88-39.51-36.85-54.47
Net Investments -0.01000-8.12-7.95010.221.081.48
Others 05.49127.480.400.080.79-2.28-3.407.740.78
Cash Flow From Financing Activity 32.3149.24-196.49-19.61139.52164.28-47.58147.43-29-10.05
Net Proceeds from Shares 000001190000
Net Proceeds from Borrowing 00000060138.0800
Interest Paid 0-18.03-10.85-12.46-6.14-23-28.58-30.65-37-33.05
Dividend Paid 0000000000
Others 32.3167.27-185.64-7.15145.6668.28-7940823
Net Cash Flow 25.53-16.45-5.38-12.631.21-1.26-78.8175.6254.6036.14
PARTICULARSMar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19
Ratios
ROE (%)17.769.538.9912.73-18.03-28.99-17.16-0.554.37-12.47
ROCE (%)14.9110.7711.0714.45-13.13-14.87-8.054.266.8-2.72
Asset Turnover Ratio0.50.430.520.570.350.390.460.50.520.49
PAT to CFO Conversion(x)0.71.023.421.58N/AN/AN/AN/A5.7N/A
Working Capital Days
Receivable Days1091401271151298683797986
Inventory Days139170132128248250239225202213
Payable Days208207148205324293274249217262

Fresenius Kabi Oncology Ltd Stock News

Fresenius Kabi Oncology Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Fresenius Kabi Oncol on 01-Jan-1970 05:30 is ₹0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Jan-1970 05:30 the market cap of Fresenius Kabi Oncol stood at ₹2,254.9.
The latest P/E ratio of Fresenius Kabi Oncol as of 01-Jan-1970 05:30 is 0.00.
The latest P/B ratio of Fresenius Kabi Oncol as of 01-Jan-1970 05:30 is 3.87.
The 52-week high of Fresenius Kabi Oncol is ₹132.6 and the 52-week low is ₹132.0.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Fresenius Kabi Oncol is ₹659.6 ( Cr.) .

About Fresenius Kabi Oncology Ltd

Dabur Pharma, a leading company for cancer research and oncology drugs, was renamed  Fresenius Kabi Oncology after its acquisition by Fresenius Kabi, the leader in infusion therapy and clinical nutrition in Europe, Latin America, Asia Pacific as well as in the US, where it is a leading supplier of IV generic drugs.

The company markets its products to various part of world namely Bangladesh, Sri Lanka, Thailand, Philippines, Malaysia, Vietnam, Myanmar, Jordan, Russia, Ukraine, Georgia, Kazakhstan, Uzbekistan, Hungary, Kenya, Nigeria, Ghana, Zimbabwe, Brazil, Venezuela, Mexico, and many more.

The manufacturing facilities are located in Bordon (U.K.), Kalyani (India) and Baddi (India). These plants are approved by the regulatory bodies of countries like Brazil, Colombia, Malaysia, Turkey, Pakistan, Ukraine, Sudan, Belarus Hungary, Jordan, Zimbabwe, Yemen.

Products

APIs- It manufactures Active Pharmaceutical Ingredients (API) for anti cancer, drug intermediate, calcium regulator, muscle relaxant, Analgesic and many more.

Oncology- Under this it has created drugs like Intaxel, Nanoxel.

Other range of generic products offered by Fresenius Kabi Oncology includes, Taxane Analogues, Alkylating Agents, Anti-Metabolites, Cytostatic Antibiotics, Cytostatic hormone therapies.

Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.